<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H68A3A2E8746541B2A8227F93EDF54952" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 1328 IH: Medical Device Nonvisual Accessibility Act of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1328</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230301">March 1, 2023</action-date><action-desc><sponsor name-id="S001145">Ms. Schakowsky</sponsor> (for herself, <cosponsor name-id="T000483">Mr. Trone</cosponsor>, <cosponsor name-id="V000131">Mr. Veasey</cosponsor>, <cosponsor name-id="B000490">Mr. Bishop of Georgia</cosponsor>, <cosponsor name-id="P000613">Mr. Panetta</cosponsor>, <cosponsor name-id="S001168">Mr. Sarbanes</cosponsor>, <cosponsor name-id="P000607">Mr. Pocan</cosponsor>, <cosponsor name-id="Q000023">Mr. Quigley</cosponsor>, <cosponsor name-id="S000510">Mr. Smith of Washington</cosponsor>, <cosponsor name-id="R000576">Mr. Ruppersberger</cosponsor>, <cosponsor name-id="B001224">Ms. Bush</cosponsor>, <cosponsor name-id="S000250">Mr. Sessions</cosponsor>, <cosponsor name-id="L000557">Mr. Larson of Connecticut</cosponsor>, <cosponsor name-id="L000551">Ms. Lee of California</cosponsor>, <cosponsor name-id="G000551">Mr. Grijalva</cosponsor>, <cosponsor name-id="C001117">Mr. Casten</cosponsor>, <cosponsor name-id="G000586">Mr. García of Illinois</cosponsor>, <cosponsor name-id="R000609">Mr. Rutherford</cosponsor>, <cosponsor name-id="L000562">Mr. Lynch</cosponsor>, <cosponsor name-id="T000468">Ms. Titus</cosponsor>, <cosponsor name-id="B001303">Ms. Blunt Rochester</cosponsor>, <cosponsor name-id="C001127">Mrs. Cherfilus-McCormick</cosponsor>, <cosponsor name-id="C001078">Mr. Connolly</cosponsor>, <cosponsor name-id="C001055">Mr. Case</cosponsor>, <cosponsor name-id="K000375">Mr. Keating</cosponsor>, <cosponsor name-id="F000466">Mr. Fitzpatrick</cosponsor>, <cosponsor name-id="D000096">Mr. Davis of Illinois</cosponsor>, <cosponsor name-id="T000481">Ms. Tlaib</cosponsor>, <cosponsor name-id="C001119">Ms. Craig</cosponsor>, <cosponsor name-id="S001185">Ms. Sewell</cosponsor>, <cosponsor name-id="H001081">Mrs. Hayes</cosponsor>, <cosponsor name-id="K000380">Mr. Kildee</cosponsor>, and <cosponsor name-id="K000382">Ms. Kuster</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to establish nonvisual accessibility standards for certain devices with digital interfaces, and for other purposes.</official-title></form><legis-body id="HBC9FD0D2F40141519B6EF71126E77224" style="OLC"><section id="HCD71D2310C7745F8B41133393E44E2EA" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medical Device Nonvisual Accessibility Act of 2023</short-title></quote>.</text></section><section id="H22A9AE77A1874ADB9F3E751C8F778F28"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text><paragraph id="H86957EDA9D8D40A292A3AFA480D1B3B6"><enum>(1)</enum><text display-inline="yes-display-inline">Rapid advances in digital technology have led to increasingly complex user interfaces for everyday products, such as life-sustaining medical devices and technologies.</text></paragraph><paragraph id="H7C209C27EB96438E9DFABC9FD22FBF43"><enum>(2)</enum><text display-inline="yes-display-inline">Many of these new devices utilize displays that can only be operated visually and require user interaction with on-screen menus and other interfaces that are inaccessible to consumers who are blind or have low-vision.</text></paragraph><paragraph id="H45059464D81641F8BD6A2BBAE96D5EDA"><enum>(3)</enum><text>Medical devices designed for use in the home are being increasingly utilized to lessen the cost of inpatient care for consumers.</text></paragraph><paragraph id="H6E0146B4DA8244E09F9BA3D3D0DDFF21"><enum>(4)</enum><text>Devices such as blood pressure monitors, sleep apnea machines, in-home chemotherapy treatments, and many others generally lack nonvisual accessibility.</text></paragraph><paragraph id="H0EAF78AA699F42089B830B54C69B520A"><enum>(5)</enum><text display-inline="yes-display-inline">If a medical device is not accessible in a nonvisual manner, a blind or low-vision individual is unable to use it privately, independently, and safely.</text></paragraph><paragraph id="H6F34B601C9D4488EAD3828435620FEE1"><enum>(6)</enum><text display-inline="yes-display-inline">Many technology companies have incorporated screen access technology functions, such as text to speech software, into products developed and sold by such companies.</text></paragraph><paragraph id="H68944BCF55D94F3BB31D458A68D054F4"><enum>(7)</enum><text>Screen access technology is not the only mechanism by which medical devices can be made accessible to blind or low-vision consumers.</text></paragraph><paragraph id="H0EF61AAB338C4D7CBE2A2A1038E690DA"><enum>(8)</enum><text display-inline="yes-display-inline">Devices that utilize these mechanisms will be more user-friendly in general by including multiple methods to confirm readings and other data, leading to less waste and fewer mistakes.</text></paragraph><paragraph id="H73603AD863A94A5E9B12A011DAB70CDC"><enum>(9)</enum><text>Devices can be designed to work with nonvisual access technology used by individuals who are blind or have low-vision at little or no extra cost as long as such compatibility is taken into consideration at the beginning of the design process.</text></paragraph><paragraph id="HC1A28E89BA3F4E8AACEE1BCD829059CD"><enum>(10)</enum><text>Consumers who are blind or have low-vision must be able to operate medical devices in an equally effective and equally integrated manner and with equivalent ease of use as consumers without disabilities.</text></paragraph></section><section id="H6AC154ACDCC04972B0E4C7BE03E5EF06"><enum>3.</enum><header>Nonvisual accessibility standards for certain devices</header><subsection id="HCE62BC5430B748118074CDA6C0BFFE7F"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 501 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/351">21 U.S.C. 351</external-xref>) is amended by adding at the end the following:</text><quoted-block style="traditional" id="H624D4CF0A27F42C69DECBE26A8C2F774" display-inline="no-display-inline"><subsection id="HD8E0A6DC9688415097DA3BD4917B686F"><enum>(k)</enum><paragraph commented="no" display-inline="yes-display-inline" id="H1C09C8DB02CA4CF19A63054C24FBC035"><enum>(1)</enum><text display-inline="yes-display-inline">Beginning on the effective date specified in section 515D(d), if it is a covered device, unless the device meets the nonvisual accessibility standard specified under section 515D or the Secretary issues a waiver with respect to the device under subparagraph (2).</text></paragraph><paragraph id="H7C0BA8394306446D91281C523BC6CB8C" indent="up1"><enum>(2)</enum><text display-inline="yes-display-inline"><italic></italic>The Secretary may waive the application of subparagraph (1) with respect to a covered device if, based on clear and convincing evidence (as determined by the Secretary) provided by the manufacturer involved, the Secretary determines that the application of such subparagraph to the device would result in a fundamental alteration to the nature of the product or an undue hardship for the manufacturer.</text></paragraph><paragraph id="H32FC6E5071B44440B5A930A3364803D4" indent="up1"><enum>(3)</enum><text>In this paragraph:</text><subparagraph id="H10B22CB0B48F42C0BBFE1799B18C14C7"><enum>(A)</enum><text display-inline="yes-display-inline">The term <term>covered device</term> means a device that—</text><clause id="H37FAF56E19D74AAD832A373B6C677938"><enum>(i)</enum><text>is classified under section 513 into class II or III;</text></clause><clause id="HD6A7B22ED2244FDEB7A4B4B243B91710"><enum>(ii)</enum><text display-inline="yes-display-inline">is cleared under section 510(k), granted marketing authorization under section 513(f)(2), or approved under section 515 after the effective date specified in section 515D(d);</text></clause><clause id="H8769F1255C214D57BF771BF991AED544"><enum>(iii)</enum><text>has a user interface; and</text></clause><clause id="HD1619F28E0BB47BFB5944F672421FD8A"><enum>(iv)</enum><text>is not intended solely for use by a health care provider or in a setting outside the home.</text></clause></subparagraph><subparagraph id="HE903799952E54CA5B5A6994DA9D2A621"><enum>(B)</enum><text display-inline="yes-display-inline">The term <term>fundamental alteration</term> means an alteration to the nature of a covered device that would render it unusable or incapable of performing an essential function.</text></subparagraph><subparagraph id="H4505F823B1A34B849A2CF2541F845B54"><enum>(C)</enum><clause commented="no" display-inline="yes-display-inline" id="HBC70B522E3B742D5B605730262CFA0AF"><enum>(i)</enum><text display-inline="yes-display-inline">The term <quote>undue hardship</quote> means an action requiring significant difficulty or expense, when considered in light of the factors set forth in clause (ii).</text></clause><clause id="H2C28A70120034BBABCFECE99258E647E" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">In determining whether application of this subparagraph would impose an undue hardship on a manufacturer of a covered device, factors to be considered may include—</text><subclause id="H093F6B69BF374CB184D1EA6E6B3C5FCB"><enum>(I)</enum><text display-inline="yes-display-inline">the nature and cost of compliance with the standard under section 515D; and</text></subclause><subclause id="H075E96AD661741F58EF4DE043C5ADDD2"><enum>(II)</enum><text display-inline="yes-display-inline">the overall financial resources of the manufacturer of a covered device.</text></subclause></clause></subparagraph><subparagraph id="HE362CB59470A4161888C4F49CD33FEED"><enum>(D)</enum><text display-inline="yes-display-inline">The term <term>user interface</term> means a screen or mobile application through which a human user interacts or communicates with the device by inputting or receiving information.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HDF5B3BCDDE194C59B5D337D7BFD27924"><enum>(b)</enum><header>Recognition of standard</header><text display-inline="yes-display-inline">The Federal Food, Drug, and Cosmetic Act is amended by inserting after section 515C (as added by <external-xref legal-doc="public-law" parsable-cite="pl/117/328">Public Law 117–328</external-xref>) the following:</text><quoted-block style="OLC" id="HA9C85584E119418FAD18B802EF74254D" display-inline="no-display-inline"><section id="HC2365BCD772444C8B590CA0FF543C4D0"><enum>515D.</enum><header>Nonvisual accessibility standards for certain devices</header><subsection id="HBC60ECCDFB6D4EB48C0089D8B9195674"><enum>(a)</enum><header>Standard</header><text display-inline="yes-display-inline">The nonvisual accessibility standard specified in this section is, with respect to a user interface of a device described in section 501(k), that the user interface is as effective in allowing blind or low-vision individuals to access information, engage in interactions, and enjoy services with the same privacy, independence, and ease of use as the user interface of the device enables individuals who do not have low-vision or are not blind.</text></subsection><subsection id="H7A200BAAC51D48C09FAFC63987EDAADB"><enum>(b)</enum><header>Training</header><text display-inline="yes-display-inline">The Secretary shall conduct training to educate manufacturers of a user interface of a device described in section 501(k) or of a device described in such section on the standards developed under subsection (a) and how to comply with such standard.</text></subsection><subsection id="H283D3E341DB04C3595A337301F12E924"><enum>(c)</enum><header>Stakeholders</header><text>In developing the standard under subsection (a) and the training to be conducted under subsection (b), the Secretary shall consult with—</text><paragraph id="H153E079F222247388FD2DB98F70B221C"><enum>(1)</enum><text display-inline="yes-display-inline">the Architectural and Transportation Barriers Compliance Board established under section 504 of the Rehabilitation Act of 1973; and</text></paragraph><paragraph id="HB2CA663C78AB453F897234F34FB4633F"><enum>(2)</enum><text display-inline="yes-display-inline">individuals who are blind or who have low-vision. </text></paragraph></subsection><subsection id="HF04A252811D146F4BB3F47B9DBE9DBD3"><enum>(d)</enum><header>Regulations</header><paragraph id="H0DBE54E754A145D6A0F14957A80A5BEC"><enum>(1)</enum><header>In general</header><text>The Secretary shall, in consultation with the Architectural and Transportation Barriers Compliance Board referred to in subsection (b)—</text><subparagraph id="H2FB7558E802541CE90DE49744FB7A0B5"><enum>(A)</enum><text>not later than 1 year after the date of the enactment of this section, issue proposed regulations to implement the standard specified under subsection (a); and</text></subparagraph><subparagraph id="H98327E2800BC41099E0365BAFD130B21"><enum>(B)</enum><text>not later than 2 years after the date of the enactment of this section, publish a final rule with respect to such proposed regulations.</text></subparagraph></paragraph><paragraph id="H563E6A105B46478F84AF5A557F544720"><enum>(2)</enum><header>Effective date</header><text>The final rule published under paragraph (1)(B) shall take effect on the date that is 1 year after the date on which such rule is published.</text></paragraph></subsection><subsection id="HFE71BAC3839745EE9ADA4CA311640441"><enum>(e)</enum><header>Authorization of appropriations</header><text>There is authorized to be appropriated to carry out this section $1,500,000 the period of fiscal years 2024 through 2025.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section></legis-body></bill> 

